Evonik Corporation manufactures and supplies specialty chemicals. It offers specialty chemicals for various applications in agriculture; automotive, transportation, and machinery; metals and mining, and oil and gas; pharmaceuticals and healthcare; printing, paints, and coatings; pulp, paper, and packaging; plastics and general industry; environment and utilities; home, lifestyle, and personal; care food, feed, and beverages; electronics and telecommunications; and construction markets. Evonik Corporation was formerly known as Evonik Degussa Corporation and changed its name to Evonik Corporation on January 1, 2013. The company was founded in 1977 and is based in Parsippany, New Jersey with ad...
299 Jefferson Road
Parsippany, NJ 07054
Founded in 1977
Evonik Corporation Announces New Distribution Agreements with The Cary Company and Dorsett & Jackson, Inc
Nov 13 14
Evonik Corporation announced that it’s Inorganic Materials Business Unit has announced new agreements with The Cary Company and Dorsett & Jackson, Inc., to broaden distribution of its silica products in the U.S. Midwest and Western regions, respectively. Previously representing Evonik’s silica product lines in Minnesota, Wisconsin, North Dakota, South Dakota, Northern Indiana, and portions of Iowa and Illinois, The Cary Company will now also cover all of Iowa, Illinois, Missouri, Kansas and Nebraska. In addition to the territories of California, Oregon, Washington, Nevada and Arizona, Dorsett & Jackson, Inc., will represent Evonik’s silica product lines in Utah, Colorado, Wyoming, Montana, and Idaho. The agreement includes ACEMATT ® Matting Agents, SIPERNAT ® and SIDENT ® Precipitated Silica, AEROSIL ® Fumed Silica, AEROXIDE ® Mixed Metal Oxides, and AERODISP ® Dispersions.
BioDelivery Sciences to Develop Long-Acting Injectable Depot Formulation of Buprenorphine with Evonik Corporation
Oct 28 14
BioDelivery Sciences International, Inc. has entered into an exclusive agreement with Evonik Corporation to develop and commercialize a proprietary, injectable microparticle formulation of buprenorphine potentially capable of providing 30 days of continuous therapy following a single subcutaneous injection. While BDSI plans to pursue an indication for the maintenance treatment of opioid dependence, the company has also secured the rights and plans to develop a product for the treatment of chronic pain in patients requiring continuous opioid therapy. BDSI has also secured options to license Evonik-owned intellectual property related to these products. As part of the agreement, BDSI will have the right to license the product(s) following the attainment of Phase I ready formulations. At that point, Evonik could receive downstream payments for milestones related to regulatory filings and subsequent NDA approvals as well as product royalties. Evonik has the exclusive rights to develop the formulation and manufacture the product(s).
Evonik Corporation Expands Precipitated Silica Site in Chester, Pennsylvania
Sep 17 14
Evonik Corporation has announced a new 20,000 metric ton expansion at its precipitated silica site in Chester, Pennsylvania.